Cargando…
Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
Rituximab (anti-CD20) is commonly used as immunotherapy against B cells, in the context of pre-transplant crossmatches, where the presence of rituximab in the tested sera with donor cells can alter their results both by flow cytometry (FCXM) as complement-dependent cytotoxicity (CDCXM) giving rise t...
Autores principales: | Colmenero Velazquez, Argentina, Iturrieta-Zuazo, Ignacio, Valdivieso Shephard, Juan Luis, Di Natale, Marisa, Rita, Claudia, Ballester González, Rubén, Castañer Alabau, José Luis, Nieto Gañán, Israel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551202/ https://www.ncbi.nlm.nih.gov/pubmed/32764391 http://dx.doi.org/10.3390/antib9030041 |
Ejemplares similares
-
Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients
por: Iturrieta-Zuazo, Ignacio, et al.
Publicado: (2020) -
False Positive B-Cells Crossmatch after Prior Rituximab Exposure of the Kidney Donor
por: Desoutter, Judith, et al.
Publicado: (2016) -
Accuracy of point‐of‐care crossmatching methods and crossmatch incompatibility in critically ill dogs
por: Marshall, Hayden, et al.
Publicado: (2020) -
Implication of a positive virtual crossmatch with negative flow crossmatch: A mind-boggler
por: Chowdhry, Mohit, et al.
Publicado: (2020) -
Immediate transfusion without crossmatching
por: Moriwaki, Y, et al.
Publicado: (2008)